Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IN8bioINAB 27 3-Year EBITDA Growth Rate is 53.40% as of Jun. 2026. GuruFocus rates INAB with a GF Score™ of 27/100. Among 1,129 Biotechnology companies, IN8bio ranks better than 87.42% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 53.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of IN8bio was 53.40% per year. The lowest was -63.40% per year. And the median was -28.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IN8bio 3-Year EBITDA Growth Rate Related Terms
INAB vs INTS, CALC, KALA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, IN8bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IN8bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IN8bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IN8bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 53.40% mean?
IN8bio (INAB) has a 3-Year EBITDA Growth Rate of 53.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IN8bio and its competitors. According to the industry distribution chart, IN8bio ranks #142 out of 1129 companies in the Biotechnology industry, placing it in the top 12.6%.
Is IN8bio's 3-Year EBITDA Growth Rate too high?
IN8bio's current 3-Year EBITDA Growth Rate is 53.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. IN8bio's value of 53.40% is 263.3% above this industry median. Based on the distribution chart, IN8bio ranks #142 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IN8bio has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's 3-Year EBITDA Growth Rate compare to INTS and CALC?
According to the Biotechnology industry distribution chart, IN8bio ranks #142 out of 1129 companies for 3-Year EBITDA Growth Rate. This places IN8bio in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. IN8bio's value of 53.40% is 263.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IN8bio's current 3-Year EBITDA Growth Rate of 53.40% is 263.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IN8bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current 3-Year EBITDA Growth Rate is 53.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current 3-Year EBITDA Growth Rate of 53.40%. The current 3-Year EBITDA Growth Rate is 53.40% and 263.3% above the Biotechnology industry median of 14.70. IN8bio's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IN8bio (INAB), the current 3-Year EBITDA Growth Rate is 53.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
27GF Score
Get the complete analysis for INAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INAB has been successfully added to your 
